Why Is SEPTERNA INC (SEPN) Stock Up Today?

SEPN stock surged 22.93 percent to $47.76 in the session, driven by a series of analyst upgrades and strong quarterly financial performance. Multiple analysts raised price targets on the stock, citing progress in Septerna’s drug pipeline and the company’s updated financial outlook. The stock also benefited from earnings that beat estimates for both revenue and GAAP EPS.

What Happened

Septerna reported Q2 2026 results with a GAAP EPS of -$0.29, which beat the consensus of -$0.49 by $0.20. Revenue totaled $26.75 million, exceeding the estimated $19.22 million. The company also disclosed $516.5 million in cash and marketable securities, with operations expected to remain funded through at least 2029. These figures were included in a Form 8-K filed on August 10, 2026.

Analyst coverage intensified over the past 36 hours, with Raymond James raising its price target to $49 from $45. Stifel and Guggenheim also increased their price targets to $49 and $51 respectively, citing progress in the pipeline and the outlook for the SEP-479 program. These upgrades contributed to the sharp upward move in the stock.

What The Data Shows

The stock’s 52-week range is $10.62 to $40.65, and it closed above the prior high of $40.65. The move pushed the market cap to $1.8 billion. Septerna remains unprofitable with a trailing twelve-month net margin of -49.9 percent and a TTM EPS of -0.81. However, revenue grew 7,295.6 percent in the trailing twelve months. The session’s volume was not provided but is expected to have exceeded the average given the magnitude of the move. Insider transactions over the past 90 days totaled eight sales worth $1.7 million, with no purchases recorded.

What To Watch

Septerna has no earnings scheduled in the immediate future. Investors will want to monitor the breadth of analyst coverage and any follow-up on the Q1 2027 data expected from the company.